The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes

R. T. Silver, J. M. Bennett, J. M. Goldman, J. L. Spivak, Ayalew Tefferi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This meeting was convened by Richard T. Silver and co-chaired by Jerry L. Spivak. It was held from 27 to 29 October 2005 in Washington, DC. Thirty-one invited speakers from seven different countries participated in the conference, which was attended by more than 300 individuals from 23 countries. As in previous years, a clinical symposium for patients, held the day before the symposium, was sponsored by the Cancer Research and Treatment Fund, Inc., New York, NY 10021. This meeting report provides a summary of the five sessions prepared and highlighted by one of the session chairs. In addition to the formal presentations on the biology, clinical aspects and management of these diverse marrow stem cell disorders, there was considerable interest generated because of the availability of several new agents that have been recently approved. A special luncheon satellite symposium was devoted to the dramatic changes in the therapeutic options for the myelodysplastic syndromes, sponsored by MGI Pharma, Inc. The keynote address was presented by Dr. George Q. Daley from Harvard Medical School and the Children's Hospital Medical Center. He reviewed the molecular steps in the formation of the Philadelphia chromosome and some of the newly described mutations leading to resistance to chemotherapy (see Section 4).

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalLeukemia Research
Volume31
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Myelodysplastic Syndromes
Philadelphia Chromosome
Medical Schools
Silver
Stem Cells
Bone Marrow
Drug Therapy
Mutation
Therapeutics
Research
Neoplasms

Keywords

  • JAK2
  • Leukemia
  • Myelodysplastic syndrome
  • Myeloproliferative

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes. / Silver, R. T.; Bennett, J. M.; Goldman, J. M.; Spivak, J. L.; Tefferi, Ayalew.

In: Leukemia Research, Vol. 31, No. 1, 01.2007, p. 11-17.

Research output: Contribution to journalArticle

Silver, R. T. ; Bennett, J. M. ; Goldman, J. M. ; Spivak, J. L. ; Tefferi, Ayalew. / The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes. In: Leukemia Research. 2007 ; Vol. 31, No. 1. pp. 11-17.
@article{658d25d95d524d39a8fc256442a37ba4,
title = "The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes",
abstract = "This meeting was convened by Richard T. Silver and co-chaired by Jerry L. Spivak. It was held from 27 to 29 October 2005 in Washington, DC. Thirty-one invited speakers from seven different countries participated in the conference, which was attended by more than 300 individuals from 23 countries. As in previous years, a clinical symposium for patients, held the day before the symposium, was sponsored by the Cancer Research and Treatment Fund, Inc., New York, NY 10021. This meeting report provides a summary of the five sessions prepared and highlighted by one of the session chairs. In addition to the formal presentations on the biology, clinical aspects and management of these diverse marrow stem cell disorders, there was considerable interest generated because of the availability of several new agents that have been recently approved. A special luncheon satellite symposium was devoted to the dramatic changes in the therapeutic options for the myelodysplastic syndromes, sponsored by MGI Pharma, Inc. The keynote address was presented by Dr. George Q. Daley from Harvard Medical School and the Children's Hospital Medical Center. He reviewed the molecular steps in the formation of the Philadelphia chromosome and some of the newly described mutations leading to resistance to chemotherapy (see Section 4).",
keywords = "JAK2, Leukemia, Myelodysplastic syndrome, Myeloproliferative",
author = "Silver, {R. T.} and Bennett, {J. M.} and Goldman, {J. M.} and Spivak, {J. L.} and Ayalew Tefferi",
year = "2007",
month = "1",
doi = "10.1016/j.leukres.2006.02.023",
language = "English (US)",
volume = "31",
pages = "11--17",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes

AU - Silver, R. T.

AU - Bennett, J. M.

AU - Goldman, J. M.

AU - Spivak, J. L.

AU - Tefferi, Ayalew

PY - 2007/1

Y1 - 2007/1

N2 - This meeting was convened by Richard T. Silver and co-chaired by Jerry L. Spivak. It was held from 27 to 29 October 2005 in Washington, DC. Thirty-one invited speakers from seven different countries participated in the conference, which was attended by more than 300 individuals from 23 countries. As in previous years, a clinical symposium for patients, held the day before the symposium, was sponsored by the Cancer Research and Treatment Fund, Inc., New York, NY 10021. This meeting report provides a summary of the five sessions prepared and highlighted by one of the session chairs. In addition to the formal presentations on the biology, clinical aspects and management of these diverse marrow stem cell disorders, there was considerable interest generated because of the availability of several new agents that have been recently approved. A special luncheon satellite symposium was devoted to the dramatic changes in the therapeutic options for the myelodysplastic syndromes, sponsored by MGI Pharma, Inc. The keynote address was presented by Dr. George Q. Daley from Harvard Medical School and the Children's Hospital Medical Center. He reviewed the molecular steps in the formation of the Philadelphia chromosome and some of the newly described mutations leading to resistance to chemotherapy (see Section 4).

AB - This meeting was convened by Richard T. Silver and co-chaired by Jerry L. Spivak. It was held from 27 to 29 October 2005 in Washington, DC. Thirty-one invited speakers from seven different countries participated in the conference, which was attended by more than 300 individuals from 23 countries. As in previous years, a clinical symposium for patients, held the day before the symposium, was sponsored by the Cancer Research and Treatment Fund, Inc., New York, NY 10021. This meeting report provides a summary of the five sessions prepared and highlighted by one of the session chairs. In addition to the formal presentations on the biology, clinical aspects and management of these diverse marrow stem cell disorders, there was considerable interest generated because of the availability of several new agents that have been recently approved. A special luncheon satellite symposium was devoted to the dramatic changes in the therapeutic options for the myelodysplastic syndromes, sponsored by MGI Pharma, Inc. The keynote address was presented by Dr. George Q. Daley from Harvard Medical School and the Children's Hospital Medical Center. He reviewed the molecular steps in the formation of the Philadelphia chromosome and some of the newly described mutations leading to resistance to chemotherapy (see Section 4).

KW - JAK2

KW - Leukemia

KW - Myelodysplastic syndrome

KW - Myeloproliferative

UR - http://www.scopus.com/inward/record.url?scp=33750730622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750730622&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.02.023

DO - 10.1016/j.leukres.2006.02.023

M3 - Article

C2 - 16620972

AN - SCOPUS:33750730622

VL - 31

SP - 11

EP - 17

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -